Phase I trial code: RD 787.36057 (MTX325-101)

Registry ID

ISRCTN20898392

Source registry

ISRCTN

Status

Recruiting

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

Mission Therapeutics Ltd.

Enrollment

158

Start date

2024-02-06

Completion date

2027-09-17

Last update

2026-08-17

Conditions

• Other

Summary

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Detailed description

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

• DRUG: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Locations

• , , Wales
• , , United Kingdom

Related clinical trials

• Helping young people to adapt their internet use and promote mental well-being in a rapidly changing world
• Testing a job crafting intervention to help make work more manageable, engaging and enjoyable for UK workers
• Understanding the impact of resistant bugs on deaths in England
• Helping local authorities to help parents: the BeST Engage Project
• Copen-SCALE: Scaling up an effective intervention to childcare institutions in Copenhagen
• Deferred registration: Quotient Sciences code: QSC303996

View on source registry